Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › IKT Leadership & Pay · Oct 20, 2026
Inhibikase Therapeutics appoints Scott Wasserman to board following Dennis Berman resignation IKT Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics appointed Scott Wasserman as a Class III director effective October 19, 2026. Concurrently, Dennis Berman resigned from the Board and his committee roles. The company granted Wasserman an initial stock option award of 310,000 shares upon joining. Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases.
More from Inhibikase Therapeutics, Inc. Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective… Aug 26, 2026 Inhibikase Therapeutics reported a net loss of $19.6 million ($0.11 per share) for the quarter ended June 30, 2026… Aug 11, 2026 On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund to swap… Jul 29, 2026 On July 23, 2026, Inhibikase Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its lead… Jul 23, 2026 At its 2026 Annual Meeting of Stockholders held on June 26, 2026, Inhibikase Therapeutics, Inc. stockholders approved… Jun 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
